In the last trading session, 1.09 million ABVC BioPharma Inc (NASDAQ:ABVC) shares changed hands as the company’s beta touched 0.74. With the company’s per share price at $0.70 changed hands at $0.12 or 19.59% during last session, the market valuation stood at $9.08M. ABVC’s last price was a discount, traded about -147.14% off its 52-week high of $1.73. The share price had its 52-week low at $0.40, which suggests the last value was 42.86% up since then.

Analysts gave the ABVC BioPharma Inc (ABVC) stock a consensus recommendation rating of Hold, calculated at a mean rating of 3.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended ABVC as a Hold, 0 felt it is a Buy and 0 rated the stock as Underweight. ABVC BioPharma Inc’s EPS for the current quarter is expected to be 0.

ABVC BioPharma Inc (NASDAQ:ABVC) trade information

Instantly ABVC was in green as seen at the end of in last trading. With action 66.97%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 18.58%, with the 5-day performance at 66.97% in the green. However, in the 30-day time frame, ABVC BioPharma Inc (NASDAQ:ABVC) is 34.54% up.

ABVC BioPharma Inc (NASDAQ:ABVC)’s Major holders

Among Mutual Funds, the top two as of Dec 31, 2024 were Fidelity Extended Market Index Fund and Vanguard Extended Market Index Fund. With 52.02 shares estimated at $36391.0 under it, the former controlled 0.40% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 0.36% of the shares, roughly 46.95 shares worth around $32844.0.